The Delhi High Court has rejected Sun Pharma's plea for interim relief against Finecure Pharmaceuticals Limited in a trademark infringement case. Sun Pharma accused Finecure of infringing on its trademark for the anti-acidity drug Pantocid.
The court ruled that Sun Pharma's delay of 13 years in approaching the court for relief weakened its claim. Finecure argued that its anti-acidity drug Pantopacid was distinct and its trademark had been registered since 2007.
The court noted that Pantocid and Pantopacid were phonetically, structurally, and visually similar, and could confuse consumers seeking acid relief. The court directed Finecure to maintain a separate account of earnings from Pantopacid and file quarterly affidavits. Sun Pharma's delay in seeking relief and lack of 'clean hands' were cited by the court in denying injunctive relief.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.